Tokyo, Japan

Kouji Matsushima

USPTO Granted Patents = 38 

 

Average Co-Inventor Count = 4.5

ph-index = 9

Forward Citations = 313(Granted Patents)


Location History:

  • Ishikawa Prefecture, JP (1998)
  • Ishikawa, JP (2000)
  • Kanazawa, JP (1997 - 2001)
  • Frederick, MD (US) (1994 - 2002)
  • Matsudo, JP (2002 - 2010)
  • Chiba, JP (2003 - 2015)
  • Tokyo, JP (2014 - 2024)

Company Filing History:

goldMedal6 out of 1,278 
 
The University of Tokyo
 patents
silverMedal5 out of 947 
 
Chugai Seiyaku Kabushiki Kaisha
 patents
bronzeMedal5 out of 3,435 
 
National Institutes of Health, a Component of the US Dept. of Health & Human Services
 patents
44 out of 14 
 
Chugai Pharmaceutical Co.
 patents
54 out of 37 
 
Telik, Inc.
 patents
64 out of 95 
 
Tokyo University of Science Foundation
 patents
73 out of 108 
 
Sanwa Kagaku Kenkyusho Co., Ltd.
 patents
83 out of 1,215 
 
The United States of America As Represented by the Department of Health
 patents
93 out of 4 
 
Idac Theranostics, Inc.
 patents
102 out of 574 
 
Ono Pharmaceutical Co., Ltd.
 patents
111 out of 13 
 
The United States of America As Represented by the Secretary, Department
 patents
121 out of 2,202 
 
The United States of America As Represented by the Secretary of
 patents
131 out of 129 
 
Dainippon Pharmaceutical Company, Limited
 patents
141 out of 3,472 
 
Toray Industries, Inc.
 patents
151 out of 128 
 
Kureha Chemical Industry Company, Limited
 patents
161 out of 7 
 
Eci, Inc.
 patents
171 out of 41 
 
Sbi Pharmaceuticals Co., Ltd.
 patents
183 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1994-2024

Loading Chart...
Loading Chart...
38 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Kouji Matsushima - Pioneering Cancer Therapies

Introduction:

Kouji Matsushima, a distinguished inventor based in Tokyo, Japan, has left an indelible mark in the field of healthcare with his groundbreaking work in developing novel cancer therapies. With an impressive portfolio of 38 patents to his name, Matsushima's innovative solutions have the potential to revolutionize the way we approach cancer treatment.

Latest Patents:

One of Matsushima's latest patents, "HMGN partial peptide and cancer therapy using the same," is a significant breakthrough in the battle against cancer. This patent unveils a novel therapeutic approach that is both effective and practical in combating cancer. The peptides derived from partial regions of HMGN1, HMGN2, HMGN4, or HMGN5, offer promising anti-tumor effects, particularly when utilized in combination with immune checkpoint regulators or specific antibodies.

Career Highlights:

Having worked with esteemed institutions like The University of Tokyo and Chugai Pharmaceutical Co., Matsushima has honed his skills and expertise in the field of biotechnology and pharmaceuticals. His commitment to innovation and patient care shines through in the patents he has successfully secured, showcasing his dedication to improving cancer therapies.

Collaborations:

Throughout his career, Matsushima has collaborated with esteemed colleagues such as Yoshiro Ishiwata and Shoji Yokochi. Together, they have synergized their knowledge and skills to push the boundaries of cancer research, leading to the development of impactful therapies that hold immense promise in the fight against this complex disease.

Conclusion:

In conclusion, Kouji Matsushima's relentless pursuit of innovation in cancer therapy has cemented his status as a visionary inventor in the medical field. His patents not only reflect his scientific acumen but also underscore his unwavering commitment to improving patient outcomes. Matsushima's contributions are poised to make a lasting impact on the landscape of cancer treatment, offering hope to patients and healthcare professionals worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…